Durvalumab for Endometrial Cancer

"Currently, this trial is being run out of 7 sites. The locations are located in Basking Ridge, New york and Harrison along with other 5 locations. To cut down on travel time and effort, patients should select the location nearest to them."

"Presently, this clinical trial is not looking for new participants. The date the study was first posted was January 1st, 2017 and the most recent update to the information on the study was on January 26th, 2022. However, there are other studies you may be eligible for; 3604 trials for patients with carcinoma and 345 Durvalumab trials are actively enrolling right now."

"The clinical trial in question is no longer active, based on information from clinicaltrials.gov. This particular study was looking for patients between January 1st 2017 and January 26th 2022. There are other options available though; at the moment, 3949 trials are actively recruiting patients."

"Since 2007, there has been an influx of research regarding Durvalumab. In the first study completed on the topic, 37 participants were observed and it was sponsored by AstraZeneca. Based on the findings,Durvalumab received its Phase 2 drug approval in 2007. Now, 345 studies are active and taking place across 1325 cities and 58 countries."

"The immunotherapy drug, durvalumab, was first studied in 2007. There are now 123 completed studies and 345 active clinical trials worldwide; with a large concentration of these studies taking place in Basking Ridge, New jersey."

"At Power, we gave Durvalumab a score of 2 on our safety scale. This is because while there is some evidence to support its safety, none exists for efficacy as it only just entered Phase 2 clinical trials."

"Most commonly, patients with unresectable stage iii non-small cell lung cancer are treated with the immunotherapy medication Durvalumab. This drug is also indicated for other conditions such as metastatic ureter urothelial carcinoma and advance directives."